Eli Lilly and Company (LLY) Stock

Eli Lilly and Company (LLY) is a Healthcare stock trading at $1176.09 (as of 2026-07-17), with a market capitalization of $1.11T and a trailing P/E of 43.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Eli Lilly and Company develops, manufactures, and markets human pharmaceutical products worldwide. Its portfolio includes diabetes medicines and therapies across oncology, immunology, and other therapeutic areas, serving patients and healthcare providers globally.

Understand Eli Lilly and Company: how it makes money

Eli Lilly makes and sells human pharmaceuticals, including diabetes medicines (such as Humalog and insulin products, plus Jardiance and Trulicity) and oncology drugs, and it earns money primarily from sales of its key products, with especially large contribution from Mounjaro.

Lilly's profitability is structurally driven by a concentrated set of high-earning medicines, shown by 'Revenue from key products' (13.8B) and the outsized role of Mounjaro (7.4B) within total revenue (19.8B).

Revenue by segment (latest quarter)
US$12.9B
Intl$6.4B

Business quality (Exceptional): High-margin business with clear revenue concentration drivers, which makes operating results particularly sensitive to the performance of key products.

Valuation: At 39× earnings, LLY trades 132% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Revenue from key products is 13.8B, and Mounjaro revenue is 7.4B (worldwide): The company has a clearly identifiable operating revenue engine tied to its major drug portfolio, including Mounjaro.
  • Gross margin is 81.9% and operating margin is 44.7% (period 2026-03-31): The business model has delivered strong profitability relative to revenue.

Bear case

  • Revenue from key products is 13.8B out of total revenue of 19.8B: Results can be vulnerable if demand, pricing, or market conditions for its largest products weaken, since a large portion of revenue comes from that smaller set.
  • The operating KPI list includes 'Monjaro (U.S. setback) revenue' of 1.9B: The business can experience meaningful pressure in the U.S. even for flagship products, which can impact consolidated results.
Valuation — source: SEC EDGAR (first-party)
Price$1176.09
Market Cap$1.11T
P/E Ratio43.8
EV / EBITDA34.5
Price / Book35.50
Price / Sales15.33
DCF Value (model)$153.97
DCF Upside vs Price-86.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$65.18B
Net Margin31.7%
Revenue Growth (YoY)55.5%
EPS Growth (YoY)169.4%
Financial Health — source: SEC EDGAR
Altman Z-Score9.60 (safe)
Piotroski F-Score8/9 (strong)
Valuation vs Sector & Industry
Stock P/E43.8
Sector P/E (Healthcare)21.4
Industry P/E (Pharmaceutical Products)17.0
vs Sector104.4%
vs Industry158.2%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Insider Sells (12mo)47
Top Institutional HolderVANGUARD GROUP INC ($88.09B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODavid A. Ricks
Employees47,000
CountryUS
IPO Date1972-06-01

Related Companies (Business model: Big Pharma / Branded Drugs; 8 closest by market cap; US-domiciled)

  • Johnson & Johnson (JNJ)
  • AbbVie Inc. (ABBV)
  • Merck & Co., Inc. (MRK)
  • Abbott Laboratories (ABT)
  • Pfizer Inc. (PFE)
  • Bristol-Myers Squibb Company (BMY)
  • Vertex Pharmaceuticals Incorporated (VRTX)
  • Regeneron Pharmaceuticals, Inc. (REGN)
LLY earnings history · LLY institutional & insider holders · LLY KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-17.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.